Valuation Charles River Laboratories International, Inc.

Stocks

Market Closed - NYSE 21:00:02 23/10/2026 BST			5-day change	1st Jan Change
345.37 ^USD	+1.68%		+15.07%	+73.14%

10-22	Labcorp, Charles River Laboratories and U.S. Food and Drug Administration Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential	CI
10-14	JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	16,488	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	64.49%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	18,592	18,212	17,782
Change	-	-36.28%	7.39%	-20.91%	3.29%	55.64%	-2.04%	-2.36%
P/E	49.4x	23.1x	25.9x	931x	-70x	85.7x	36.9x	32.7x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	5.3x	4.65x	4.07x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	2.5x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	4.21x	4.11x	3.88x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	4.75x	4.53x	4.18x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	18.2x	16.4x	15x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	22.6x	19.8x	17.3x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	61.8x	35.5x	35.2x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	1.62%	2.82%	2.84%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	4.03	9.358	10.57
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,917	4,016	4,251
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,021	1,108	1,187
EBIT ¹	742.1	834	838.8	805.9	793.9	822.5	922.1	1,026
Net income ¹	391	486.2	474.6	10.3	-144.3	187	436.8	488.7
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,105	1,725	1,294
Reference price ²	375.34	218.92	238.84	186.16	203.66	345.37	345.37	345.37
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	16/02/22	22/02/23	14/02/24	19/02/25	18/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	85.69x	4.75x	18.22x	-.--%	16.49B
WUXI APPTEC CO., LTD.	18.83x	6.63x	13.18x	1.58%	64.69B
ARGENX SE	30.16x	7.93x	26.43x	0.05%	54.78B
LONZA GROUP AG	36.79x	6.53x	19.51x	0.88%	53.49B
IQVIA HOLDINGS INC.	35.59x	3.45x	14.87x	-.--%	45.98B
BEONE MEDICINES AG	49.71x	5.74x	31.52x	-.--%	42.94B
REVOLUTION MEDICINES, INC.	-19.41x	187.75x	-20.66x	-.--%	40.08B
CELLTRION, INC.	28.93x	8.21x	21.27x	0.37%	33.52B
GENMAB A/S	32.66x	5.97x	20.09x	-.--%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	27.67x	5.83x	15.12x	-.--%	23.97B
Average	32.66x	24.28x	15.96x	0.29%	39.96B
Weighted average by Cap.	29.15x	24.47x	16.03x	0.41%